{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:46:39Z","timestamp":1772264799408,"version":"3.50.1"},"reference-count":96,"publisher":"The Japanese Society for Medical Mycology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Mycology Journal"],"published-print":{"date-parts":[[2026,1,31]]},"DOI":"10.3314\/mmj.26.002","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T22:11:40Z","timestamp":1772230300000},"page":"41-52","source":"Crossref","is-referenced-by-count":0,"title":["Control of Fungal Infections After Chemotherapy for Hematologic Diseases and After Hematopoietic Stem Cell Transplantation"],"prefix":"10.3314","volume":"67","author":[{"given":"Tatsuo","family":"Oyake","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1842","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Kato H, Fujita H, Akiyama N, Kimura S, Hiramoto N, Hosono N, et al: Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols. Support Care Cancer 26: 4187–98, 2018.","DOI":"10.1007\/s00520-018-4292-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al: Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50: 1091–100, 2010.","DOI":"10.1086\/651263"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, et al: Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15: e327–40, 2014.","DOI":"10.1016\/S1470-2045(14)70017-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Girmenia C, Raiola AM, Piciocchi A, Algarotti A, Stanzani M, Cudillo L, et al: Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 20: 872–80, 2014.","DOI":"10.1016\/j.bbmt.2014.03.004"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Papanicolaou GA, Chen M, He N, Martens MJ, Kim S, Batista MV, et al: Incidence and impact of fungal infections in post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical hematopoietic cell transplantation: A center for international blood and marrow transplant research analysis. Transplant Cell Ther 30: 114.e1–114.e16, 2024.","DOI":"10.1016\/j.jtct.2023.09.017"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kume H, Yamazaki T, Togano T, Abe M, Tanuma H, Kawana S, et al: Epidemiology of visceral mycoses in autopsy cases in Japan: comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in Annual of Pathological Autopsy Cases in Japan. Med Mycol J 52: 117–27, 2011.","DOI":"10.3314\/jjmm.52.117"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al: Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15: 1143–238, 2009.","DOI":"10.1016\/j.bbmt.2009.06.019"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Wald A, Leisenring W, van Burik JA, Bowden RA: Epidemiology of Aspergillus<\/i> infections in a large cohortof patients undergoing bone marrow transplantation. J Infect Dis 175: 1459–66, 1997.","DOI":"10.1086\/516480"},{"key":"9","unstructured":"9) Committee for the Development of Guidelines for Deep Mycosis: Guidelines for diagnosis and treatment of deep mycosis 2014. Kyowa Kikaku, Tokyo, 2014. (in Japanese)"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Portugal RD, Garnica M, Nucci M: Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol 27: 3849–54, 2009.","DOI":"10.1200\/JCO.2008.21.0856"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kimura S, Oshima K, Sato K, Sato M, Terasako K, Nakasone H, et al: Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 16: 1355–61, 2010.","DOI":"10.1016\/j.bbmt.2010.04.012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kanda Y, Kimura SI, Iino M, Fukuda T, Sakaida E, Oyake T, et al: D-index-guided early antifungal therapy versus empiric antifungal therapy for persistent febrile neutropenia: A randomized controlled noninferiority trial. J Clin Oncol 38: 815–22, 2020.","DOI":"10.1200\/JCO.19.01916"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Girmenia C, Barosi G, Piciocchi A, Arcese W, Aversa F, Bacigalupo A, et al: Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 20: 1080–8, 2014.","DOI":"10.1016\/j.bbmt.2014.02.018"},{"key":"14","unstructured":"14) Donnelly JP, Chen SC, Kau\ufb00man CA, Steinbach WJ, Baddley JW, Verweij PE, et al: Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 71: 1367–76, 2020."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al: Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 48: 265–73, 2009.","DOI":"10.1086\/595846"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Burgos A, Zaoutis TE, Dvorak CC, Hoffman JA, Knapp KM, Nania JJ, et al: Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 121: e1286–94, 2008.","DOI":"10.1542\/peds.2007-2117"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al: Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44: 373–9, 2007.","DOI":"10.1086\/509917"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49: 3640–5, 2005.","DOI":"10.1128\/AAC.49.9.3640-3645.2005"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Chamilos G, Lewis RE, Kontoyiannis DP: Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 47: 503–9, 2008.","DOI":"10.1086\/590004"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Marr KA, Bow E, Chiller T, Maschmeyer G, Ribaud P, Segal B, et al: Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 44: 483–7, 2009.","DOI":"10.1038\/bmt.2009.259"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fl\u00fcckiger U, Fr\u00eare P, et al: European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3: 2009 update. Bone Marrow Transplant 46: 709–18, 2011.","DOI":"10.1038\/bmt.2010.175"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kimura SI, Kanda Y, Oyake T, Yamaguchi H, Fujiwara SI, Okamoto A, et al: Fungal biomarker monitoring and CT scans for early detection of invasive fungal disease in neutropenic hematological patients. J Infect 84: 80–6, 2022.","DOI":"10.1016\/j.jinf.2021.10.018"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Groll AH, Pana D, Lanternier F, Mesini A, Ammann RA, Averbuch D, et al: 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol 22: e254–69, 2021.","DOI":"10.1016\/S1470-2045(20)30723-3"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al: Practice guidelines for the Diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63: e1–e60, 2016.","DOI":"10.1093\/cid\/ciw326"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52: e56–93, 2011.","DOI":"10.1093\/cid\/cir073"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Morrissey CO, Gilroy NM, Macesic N, Walker P, Ananda-Rajah M, May M, et al: Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. Intern Med J 44: 1298–314, 2014.","DOI":"10.1111\/imj.12596"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Maertens J, Lodewyck T, Donnelly JP, Chantepie S, Robin C, Blijlevens N, et al: Empiric vs preemptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: A randomized trial of the European Organization for Research and Treatment of Cancer. Clin Infect Dis 76: 674–82, 2023.","DOI":"10.1093\/cid\/ciac623"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Santolaya ME, Alvarez AM, Acu\u00f1a M, Avil\u00e9s CL, Salgado C, Tordecilla J, et al: E\ufb03cacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial. J Antimicrob Chemother 73: 2860–6, 2018.","DOI":"10.1093\/jac\/dky244"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al: E\ufb03cacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: A prospective, randomized, double-blind study. J Infect Dis 171: 1545–52, 1995.","DOI":"10.1093\/infdis\/171.6.1545"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326: 845–51, 1992.","DOI":"10.1056\/NEJM199203263261301"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39: 1407–16, 2004.","DOI":"10.1086\/422312"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al: Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116: 5111–8, 2010.","DOI":"10.1182\/blood-2010-02-268151"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Maertens JA, Girmenia C, Br\u00fcggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al: European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 73: 3221–30, 2018.","DOI":"10.1093\/jac\/dky286"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356: 348–59, 2007.","DOI":"10.1056\/NEJMoa061094"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356: 335–47, 2007.","DOI":"10.1056\/NEJMoa061098"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Hayashi Y, Kanda Y, Nakamae H, Kanamori H, Ohashi K, Hidaka M, et al: Voriconazole vs. itraconazole for antifungal prophylaxis in patients with GVHD: A randomized trial. Biol Blood Marrow Transplant 20: S91, 2014.","DOI":"10.1016\/j.bbmt.2013.12.117"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340: 764–71, 1999.","DOI":"10.1056\/NEJM199903113401004"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351: 1391–402, 2004.","DOI":"10.1056\/NEJMoa040446"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, et al: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: A randomized, controlled trial. Ann Intern Med 135: 412–22, 2001.","DOI":"10.7326\/0003-4819-135-6-200109180-00010"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346: 225–34, 2002.","DOI":"10.1056\/NEJM200201243460403"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al: Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48: 1042–51, 2009.","DOI":"10.1086\/597395"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Gamaletsou MN, Walsh TJ, Zaoutis T, Pagoni M, Kotsopoulou M, Voulgarelis M, et al: A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect 20: O50–7, 2014.","DOI":"10.1111\/1469-0691.12312"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al: Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 62: e1–50, 2016.","DOI":"10.1093\/cid\/civ933"},{"key":"44","unstructured":"44) Committee for the Development of Guidelines for the Diagnosis and Treatment of Candidasis, The Japanese Society for Medical Mycology: Clinical practice guidelines for the management of invasive candidiasis 2021. The Japanese Society for Medical Mycology, Tokyo, 2021. (in Japanese)"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, et al: ESCMID* guideline for the diagnosis and management of Candida<\/i> diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18: 53–67, 2012.","DOI":"10.1111\/1469-0691.12041"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Cornely OA, Marty FM, Stucker F, Pappas PG, Ullmann AJ: E\ufb03cacy and safety of micafungin for treatment of serious Candida<\/i> infections in patients with or without malignant disease. Mycoses 54: e838–47, 2011.","DOI":"10.1111\/j.1439-0507.2011.02045.x"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al: ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 102: 433–44, 2017.","DOI":"10.3324\/haematol.2016.152900"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366: 1435–42, 2005.","DOI":"10.1016\/S0140-6736(05)67490-9"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L, Rotstein C, et al: Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida<\/i> infections: The ACTIVE Trial. Clin Infect Dis 68: 1981–9, 2019.","DOI":"10.1093\/cid\/ciy827"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347: 408–15, 2002.","DOI":"10.1056\/NEJMoa020191"},{"key":"51","unstructured":"51) Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al: Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus<\/i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387: 760–9, 2016."},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Maertens JA, Rahav G, Lee DG, Ponce-de-Le\u00f3n A, Ram\u00edrez S\u00e1nchez IC, Klimko N, et al: Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet 397: 499–509, 2021.","DOI":"10.1016\/S0140-6736(21)00219-1"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34: 563–71, 2002.","DOI":"10.1086\/324620"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, et al: Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106: 2641–5, 2005.","DOI":"10.1182\/blood-2005-02-0733"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Schwartz S, Reisman A, Troke PF: The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection 39: 201–10, 2011.","DOI":"10.1007\/s15010-011-0108-6"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Schwartz S, Cornely OA, Hamed K, Marty FM, Maertens J, Rahav G, et al: Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol 58: 417–24, 2020.","DOI":"10.1093\/mmy\/myz103"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, et al: Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 56: 745–55, 2005.","DOI":"10.1093\/jac\/dki288"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44: 1289–97, 2007.","DOI":"10.1086\/514341"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Hiemenz JW, Raad II, Maertens JA, Hachem RY, Saah AJ, Sable CA, et al: E\ufb03cacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis 29: 1387–94, 2010.","DOI":"10.1007\/s10096-010-1013-0"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Cornely OA, Vehreschild JJ, Vehreschild MJ, W\u00fcrthwein G, Arenz D, Schwartz S, et al: Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother 55: 5798–803, 2011.","DOI":"10.1128\/AAC.05134-11"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al: Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 162: 81–9, 2015.","DOI":"10.7326\/M13-2508"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Caillot D, Thi\u00e9baut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, et al: Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 110: 2740–6, 2007.","DOI":"10.1002\/cncr.23109"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Marr KA, Boeckh M, Carter RA, Kim HW, Corey L: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39: 797–802, 2004.","DOI":"10.1086\/423380"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Panackal AA, Parisini E, Proschan M: Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis 28: 80–94, 2014.","DOI":"10.1016\/j.ijid.2014.07.007"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Candoni A, Caira M, Cesaro S, Busca A, Giacchino M, Fanci R, et al: Multicentre surveillance study on feasibility, safety and e\ufb03cacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. Mycoses 57: 342–50, 2014.","DOI":"10.1111\/myc.12161"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, Alexander BD, et al: Molecular identification of Aspergillus<\/i> species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 47: 3138–41, 2009.","DOI":"10.1128\/JCM.01070-09"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Alastruey-Izquierdo A, Mellado E, Pel\u00e1ez T, Pem\u00e1n J, Zapico S, Alvarez M, et al: Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother 57: 3380–7, 2013.","DOI":"10.1128\/AAC.00383-13"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Toyotome T: Causative agents of aspergillosis including cryptic Aspergillus<\/i> species and A. fumigatus<\/i>. Med Mycol J 57: J149–J54, 2016. [Article in Japanese]","DOI":"10.3314\/mmj.16.005"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, et al: Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19: 253–9, 2001.","DOI":"10.1200\/JCO.2001.19.1.253"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, et al: ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 20: 5–26, 2014.","DOI":"10.1111\/1469-0691.12371"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, et al: Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 98: 492–504, 2013.","DOI":"10.3324\/haematol.2012.065110"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Kontoyiannis DP, Lewis RE: How I treat mucormycosis. Blood 118: 1216–24, 2011.","DOI":"10.1182\/blood-2011-03-316430"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, et al: Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother 70: 3116–23, 2015.","DOI":"10.1093\/jac\/dkv236"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Tashiro M, Namie H, Ito Y, Takazono T, Kakeya H, Miyazaki Y, et al: Prognostic association of liposomal amphotericin B doses above 5 mg\/kg\/d in mucormycosis: A nationwide epidemiologic and treatment analysis in Japan. Open Forum Infect Dis 10: ofad480, 2023.","DOI":"10.1093\/ofid\/ofad480"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Kontoyiannis DP, Azie N, Franks B, Horn DL: Prospective antifungal therapy (PATH) alliance\u00ae<\/sup>: focus on mucormycosis. Mycoses 57: 240–6, 2014.","DOI":"10.1111\/myc.12149"},{"key":"76","unstructured":"76) Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al: Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 16: 828–37, 2016."},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Vitale RG, de Hoog GS, Schwarz P, Dannaoui E, Deng S, Machouart M, et al: Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. J Clin Microbiol 50: 66–75, 2012.","DOI":"10.1128\/JCM.06133-11"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Drogari-Apiranthitou M, Mantopoulou FD, Skiada A, Kanioura L, Grammatikou M, Vrioni G, et al: In vitro<\/i> antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrobial Chemother 67: 1937–40, 2012.","DOI":"10.1093\/jac\/dks137"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al: Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 50: 126–33, 2006.","DOI":"10.1128\/AAC.50.1.126-133.2006"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42: e61–5, 2006.","DOI":"10.1086\/500212"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jim\u00e9nez JL, et al: Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother 71: 1747, 2016.","DOI":"10.1093\/jac\/dkw079"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Maertens J, Cornely OA, Ullmann AJ, Heinz WJ, Krishna G, Patino H, et al: Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother 58: 3610–7, 2014.","DOI":"10.1128\/AAC.02686-13"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, et al: Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrobial Chemother 72: 3406–13, 2017.","DOI":"10.1093\/jac\/dkx263"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Vironneau P, Kania R, Morizot G, Elie C, Garcia-Hermoso D, Herman P, et al: Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival. Clin Microbiol Infect 20: O336–9, 2014.","DOI":"10.1111\/1469-0691.12408"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE: Pulmonary mucormycosis: results of medical and surgicaltherapy. Ann Thorac Surg 57: 1044–50, 1994.","DOI":"10.1016\/0003-4975(94)90243-7"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Fournier S, Pavageau W, Feuillhade M, Deplus S, Zagdanski AM, Verola O, et al: Use of voriconazole to successfully treat disseminated Trichosporon asahii<\/i> infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 21: 892–6, 2002.","DOI":"10.1007\/s10096-002-0841-y"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Francisco EC, Dieleman C, Hagen F, Colombo AL; Trichosporon Brazilian Network: In vitro<\/i> activity of isavuconazole against clinically relevant Trichosporon<\/i> species: a comparative evaluation of EUCAST broth microdilution and MIC Test Strip methods. J Antimicrob Chemother 78: 817–22, 2023.","DOI":"10.1093\/jac\/dkad016"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Chen SC, Perfect J, Colombo AL, Cornely OA, Groll AH, Seidel D, et al: Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis 21: e375–e86, 2021.","DOI":"10.1016\/S1473-3099(21)00203-6"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O; European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology: ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect 20: 76–98, 2014.","DOI":"10.1111\/1469-0691.12360"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Feugray G, Krzisch D, Dehais M, Razakandrainibe R, Gargala G, Favennec L, et al: Successful treatment of Trichosporon asahii<\/i> fungemia with isavuconazole in a patient with hematologic malignancies. Infect Drug Resist 12: 2015–8, 2019.","DOI":"10.2147\/IDR.S211148"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Venditti M, Micozzi A, Gentile G, Polonelli L, Morace G, Bianco P, et al: Invasive Fusarium solani<\/i> infections in patients with acute leukemia. Rev Infect Dis 10: 653–60, 1998.","DOI":"10.1093\/clinids\/10.3.653"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Yu J, Chen Y, Fang J, Zhang K: Successful treatment of disseminated fusariosis in a patient with acute lymphoblastic leukemia: A case report and literature review. Medicine (Baltimore) 98: e16246, 2019.","DOI":"10.1097\/MD.0000000000016246"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Tortorano AM, Richardson M, Roilides E, van Diepeningen A, Caira M, Munoz P, et al: ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium<\/i> spp., Scedosporium<\/i> spp. and others. Clin Microbiol Infect 20: 27–46, 2014.","DOI":"10.1111\/1469-0691.12465"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, et al: International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 54: 4446–50, 2010.","DOI":"10.1128\/AAC.00286-10"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al: Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 42: 1398–403, 2006.","DOI":"10.1086\/503425"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Husain S, Mu\u00f1oz P, Forrest G, Alexander BD, Somani J, Brennan K, et al: Infections due to Scedosporium apiospermum<\/i> and Scedosporium prolificans<\/i> in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 40: 89–99, 2005.","DOI":"10.1086\/426445"}],"container-title":["Medical Mycology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/67\/1\/67_41\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:45:02Z","timestamp":1772253902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/67\/1\/67_41\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3314\/mmj.26.002","relation":{},"ISSN":["2185-6486","2186-165X"],"issn-type":[{"value":"2185-6486","type":"print"},{"value":"2186-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]}}}